Engineering the Intestinal Lymphatic Transport of Oral Nanoparticles to Educate Macrophages for Cancer Combined Immunotherapy

Xu, Lei; Weng, Shufeng; Li, Shengqi; Wang, Ke; Shen, Yu; Xu, Ying; Tang, Cui; Chen, Yin

doi:10.1021/acsnano.3c02985

Cited by 13 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polyethylene glycol-polycaprolactone (PEG-PCL) polymer loaded with MUC1 inhibitor and DOX exhibited reliable safety and excellent anti-tumor growth ability in ascites carcinoma murine model 130 . Signal regulatory protein α siRNA and pMUC1 (a therapeutic pDNA vaccine) encapsulated with trimethyl chitosan could accumulated in the macrophages in lymph nodes and tumor tissues via oral administration, resulting in a strong cellular immune response 131 .…”

Section: Muc1 and Treatmentmentioning

confidence: 99%

Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

Tong,

Dong,

Liang

2024

J. Cancer

View full text Add to dashboard Cite

Mucin1 is a highly glycosylated type 1 transmembrane mucin that ranks second among 75 tumor-related antigens published by the National Cancer Institute, and has been identified as a possible therapeutic target over the past 30 years. MUC1 plays an important role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and cellular-abelsongene, which are of importance in the pathogenesis of various malignant tumors. Targeting MUC1 has been shown to be an effective way to induce tumor cell death in vivo and in vitro models. In recent years, a number of therapeutic strategies targeting MUC1 have been developed and their value for tumor therapy have been demonstrated experimentally. This review summarizes recent findings on the structure of MUC1, its expression in different tumors and its involved mechanism pathways, with emphasis on new progress in cancer therapy which related MUC1 in the past decade and evaluates their therapeutic effect.

show abstract

Section: Muc1 and Treatmentmentioning

confidence: 99%

Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

Tong,

Dong,

Liang

2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The nanoparticles blocked the signaling axis to promote M2-to-M1 repolarization . Similarly, Xu et al developed trimethyl chitosan nanoparticles modified with mannose and glycocholic acid . These nanoparticles encapsulated SIRP α-siRNA and MUC1 pDNA.…”

Section: Reversal Of the Immunosuppressive Microenvironmentmentioning

confidence: 99%

Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer

Wang,

Huang,

Chen

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is an aggressive subtype with the worst prognosis and highest recurrence rates. The treatment choices are limited due to the scarcity of endocrine and HER2 targets, except for chemotherapy. However, the side effects of chemotherapy restrict its long-term usage. Immunotherapy shows potential as a promising therapeutic strategy, such as inducing immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy. Nanotechnology offers unique advantages in the field of immunotherapy, such as improved delivery and targeted release of immunotherapeutic agents and enhanced bioavailability of immunomodulators. As well as the potential for combination therapy synergistically enhanced by nanocarriers. Nanoparticles-based combined application of multiple immunotherapies is designed to take the tactics of enhancing immunogenicity and reversing immunosuppression. Moreover, the increasing abundance of biomedical materials holds more promise for the development of this field. This review summarizes the advances in the field of nanoparticle-mediated immunotherapy in terms of both immune strategies for treatment and the development of biomaterials and presents challenges and hopes for the future.

show abstract

“…They accumulated within macrophages in lymph nodes and tumor tissues through the intestinal lymphatic transport pathway, leading to macrophage repolarization to the M1 phenotype and exerting a strong cellular immune response. [ 181 ]…”

Section: Targeting Cancer Treatment Resistance With Different Mechani...mentioning

confidence: 99%

Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer

He,

Gou,

Zhang

et al. 2023

Small Methods

View full text Add to dashboard Cite

Despite the tremendous progress in cancer treatment in recent decades, cancers often become resistant due to multiple mechanisms, such as intrinsic or acquired multidrug resistance, which leads to unsatisfactory treatment effects or accompanying metastasis and recurrence, ultimately to treatment failure. With a deeper understanding of the molecular mechanisms of tumors, researchers have realized that treatment designs targeting tumor resistance mechanisms would be a promising strategy to break the therapeutic deadlock. Nanodelivery systems have excellent physicochemical properties, including highly efficient tissue‐specific delivery, substantial specific surface area, and controllable surface chemistry, which endow nanodelivery systems with capabilities such as precise targeting, deep penetration, responsive drug release, multidrug codelivery, and multimodal synergy, which are currently widely used in biomedical researches and bring a new dawn for overcoming cancer resistance. Based on the mechanisms of tumor therapeutic resistance, this review summarizes the research progress of nanodelivery systems for overcoming tumor resistance to improve therapeutic efficacy in recent years and offers prospects and challenges of the application of nanodelivery systems for overcoming cancer resistance.

show abstract

Engineering the Intestinal Lymphatic Transport of Oral Nanoparticles to Educate Macrophages for Cancer Combined Immunotherapy

Cited by 13 publications

References 48 publications

Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer

Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer

Contact Info

Product

Resources

About